“We are still hoping for an approval in H2, but we are also at the same time acknowledging the fact that the agenda and the workload for the FDA is is is very heavy. And therefore, it is clear that we don't have a certainty that we will give we will get this PMTA in twenty five. And and and and that could move, of course, to twenty twenty six.”

In context

“those, can you talk a bit about some of the drivers of the reacceleration in IMS and sort of the sustainability for the second half of the year. Thank you. Emmanuel Babeau: Sure, Eric. So first on on the US. So mean, we don't have anything new to report on the potential PMTA for for for IQOS Illuma. I think everybody can see that FDA is resuming activity on on PMTA, and that's good news. As far as we are concerned, and this is public information, there is now for the renewal of the MRTP on IQOS three, there is a a tobacco product scientific advisory committee that has been scheduled. There, I've also opened a docket for a a zine m r t So number of things are happening, and and and that's what we we we know for for the time being. So I I have nothing new to report on the PMT for IQOSYUMA. We are still hoping for an approval in H2, but we are also at the same time acknowledging the fact that the agenda and the workload for the FDA is is is very heavy. And therefore, it is clear that we don't have a certainty that we will give we will get this PMTA in twenty five. And and and and that could move, of course, to twenty twenty six. On the second question on the reason for the acceleration of IQOS, I I mentioned, I think, many of them. I think it's really, you know, Europe, where you have now the effect of the characterizing flavor ban that are waning and a number of markets reaccelerating. Some markets doing really, you know, very strong performance I I mentioned some of them, like, you Spain, Germany, Romania, Bulgaria. It's great to see Italy reaccelerating as well. So I would say momentum is rebuilding. Now there will be some phasing last year on the performance in Europe, but I think we are expecting a nice performance overall for H2. And outside Europe, expect continued very nice performance from Japan and have been elaborating on the trend there where we continue to do very well. And there are all these new gr”